Ушбу иш иқтибос қилган ишлар

23 та иш

Иш: Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan

1. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011

   Dilrabo Ulmasova, G Uzakova, M N Tillyashayhov +17

   МақолаTuberculosis Research and EpidemiologyEurosurveillance201315 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.163910

2. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

   Armand Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim +4

   Мақола201011 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.027992

3. Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures

   Helen Cox, Stobdan Kalon, Sholpan Allamuratova +6

   Мақола200711 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.163905

4. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

   Shama D. Ahuja, David Ashkin, Monika Avendano +70

   Шарҳ мақола20127 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.027993

5. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis

   Mayara Lisboa Bastos, Hamidah Hussain, Karin Weyer +82

   Шарҳ мақола20144 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.034193

6. Counting Pyrazinamide in Regimens for Multidrug-Resistant Tuberculosis

   Molly F. Franke, Mercedes C. Becerra, Dylan B. Tierney +5

   Мақола20153 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.027991

7. Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis

   Kwok Chiu Chang, Chi Chiu Leung, Wing‐Wai Yew +4

   Мақола20122 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.034196

8. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

   Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt +16

   Мақола20152 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.364686

9. A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis

   Michael G. Whitfield, Heidi M. Soeters, Robin M. Warren +5

   Шарҳ мақола20152 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.378768

10. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378767

11. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378769

12. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378770

13. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378771

14. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378772

15. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378773

16. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378774

17. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378775

18. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378776

19. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378777

20. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378778

21. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378779

22. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378780

23. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.378781